目的 探讨布地格福联合无创呼吸机对改善慢性阻塞性肺病急性加重期(acute exacerbation of chronic ob-structive pulmonary disease，AECOPD)患者肺功能的影响。方法 选取2020年12月-2022年12月在洛阳市第一人民医院诊治的AECOPD患者80例，随机分为两组，对照组40例和研究组40例，对照组给予布地格福三联吸入剂治疗，研究组在对照组的基础上联合无创呼吸机治疗，比较两组治疗前后的肺功能指标、动脉血气分析结果、炎症因子，以及临床治疗疗效。结果 与治疗前比较，两组一氧化碳弥散量(diffusing copacity of the lungs for carbon monoxide，DLCO)、第一秒用力呼气容积(first second forced expiratory volume，FEV1)/用力肺活量(forced vital capacity，FVC)、FEV，升高，差异有统计学意义(P＜0。05)，且与对照组比较，研究组治疗后DLCO、FEV1/FVC、FEV1水平更高，差异有统计学意义(P＜0。05)。与治疗前比较，两组治疗后动脉血氧分压(arterial oxygen partial pressure，PaO2)升高，差异有统计学意义(P＜0。05)，动脉血二氧化碳分压(rterial carbon dioxide partial pressure，PaCO2)降低，差异有统计学意义(P＜0。05)，且与对照组比较，研究组治疗后PaO2更高(P＜0。05)，PaCO2更低(P＜0。05)。与治疗前比较，两组治疗后降钙素原(procalcitonin，PCT)、C反应蛋白(C-reactive pro-tein，CRP)降低，差异有统计学意义(P＜0。05)，且与对照组比较，研究组PCT、CRP更低，差异有统计学意义(P＜0。05)。相较于对照组的治疗总有效率(80。00％)，研究组总有效率(95。00％)更高(P＜0。05)。结论 布地格福联合无创呼吸机治疗AECOPD患者，可提升患者的肺功能，减轻患者的炎症反应，帮助提高患者的治疗效果。
Study on combination of budesonide and glucuronium bromide and fumarate with a non-invasive ventilator to improve lung function in patients with acute exacerbation of chronic obstructive pulmonary disease
Objective To explore the effect of budesonide/glucuronium bromide/fumarate formoterol comb ined with non-invasive ventilator on improving lung function in patients with acute exacerbation of chronic obstructive pulmonary dis-ease(AECOPD).Methods Totally 80 AECOPD patients who were diagnosed and treated in the Luoyang First Peoples Hos-pital from December 2020 to December 2022 were randomly divided into two groups,40 cases in the control group and 40 cases in the study group.The control group was treated with budesonide/glucuronium bromide/fumarate triple inhaler,and the study group was treated with non-invasive respiratory therapy on the basis of the control group.The lung function indicators,arterial blood gas analysis results,inflammatory factors,and clinical treatment efficacy of the two groups were compared before and after treatment.Results After treatment,the diffusing capacity of the lungs for carbon monoxide(DLCO),first second forced expiratory volume(FEV,)/forced vital capacity(FVC),and FEV,of both groups increased compared to that before treatment(P＜0.05),and the DLCO,FEV1/FVC,and FEV1 of the study group were significantly higher than those of the control group(P＜0.05).After treatment,the arterial oxygen partial pressure(PaO2)of both groups increased compared to that before treatment(P＜0.05),and the arterial carbon dioxide partial pressure(PaC02)of both groups decreased com-pared that to before treatment(P＜0.05).The PaO2 of the study group was significantly higher than that of the control group(P＜0.05),and the PaCO2 of the study group was significantly lower than that of the control group(P＜0.05).After treat-ment,two groups of procalcitonin(PCT)and C-reactive protein(CRP)decreased compared to that before treatment(P＜0.05),and the PCT and CRP in the study group were significantly lower than those in the control group(P＜0.05).The total effective rate of clinical treatment in the research group was 95.00％,significantly higher than the 80.00％in the control group(P＜0.05).Conclusion The combination of budesonide/glucuronium bromide/fumarate formoterol with non-invasive ventilator in the treatment of AECOPD patients can effectively improve lung function,arterial blood gas analysis re-sults,reduce inflammatory reactions,and improve clinical treatment efficacy.
NETL
NSTL
万方数据
